DSSG Group: Gastrointestinal

Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

This study will asses the antitumor activity and safety of Zolbetuximab (IMAB362) in combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM)

Incurable recurrent, locally advanced or metastatic pancreatic adenocarcinoma.

The trial is designed to establish whether adding a vitamin D analogue, Paricalcitol, to standard chemotherapy treatment, Gemcitabine and Nab-paclitaxel, can improve the outcomes for patients with advanced pancreatic cancer.

Bile duct cancer that is inoperable or has spread, in patients that test positive for FGFR2 gene fusion, or, FGFR2 gene mutations or amplifications.

To investigate the effects of the drug derazantinib (formerly ARQ 087) in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholangiocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion or FGFR2 gene mutations or amplifications.

Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement

The purpose of this trial is to evaluate the efficacy of pemigatinib versus standard chemotherapy in the first-line treatment of patients with Unresectable or Metastatic Cholangiocarcinoma, whos tumors harbor FGFR2 gene rearrangement.

Advanced oesophago-gastric or colorectal cancer

The purpose of this trial is to determine the safety and efficacy of the drug lithium and the optimum dose when used with standard chemotherapy.

Hepatocellular Carcinoma

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation (KEYNOTE-937).

Patients with cancer of the colon which has spread (metastasised).

The aim of the study is to identify and confirm one or more biomarkers (a biological substance) in blood and/or tissue, which will help us to identify the patients, who are going to respond to their treatment.